High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F19%3A00107306" target="_blank" >RIV/00216224:14310/19:00107306 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/19:00071049

Výsledek na webu

<a href="http://www.jcancer.org/v10p1393.htm" target="_blank" >http://www.jcancer.org/v10p1393.htm</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.7150/jca.29530" target="_blank" >10.7150/jca.29530</a>

Jazyk výsledku

angličtina

Název v původním jazyce

High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma

Popis výsledku v původním jazyce

Colorectal cancer (CRC) represents a serious challenge for oncologists due to high incidence and large heterogeneity. Prognostic factors are needed to stratify patients according to risk of disease progression. In this study, we report that high expression of c-Myb protein, determined by immunohistochemistry (IHC), associates with better overall and disease-free survival (OS, DFS) in a cohort of 103 patients. Although MYB has been previously considered to act as oncogene in CRC, our further analysis of datasets deposited in PrognoScan and SurvExpress databases confirmed that high MYB expression largely associates with good prognosis in CRC. As therapies targeting c-Myb have been developed and tested in preclinical studies, we believe that further studies are needed for detailed understanding of c-Myb function in CRC, before the c-Myb-targeted therapy enters clinical trials.

Název v anglickém jazyce

High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma

Popis výsledku anglicky

Colorectal cancer (CRC) represents a serious challenge for oncologists due to high incidence and large heterogeneity. Prognostic factors are needed to stratify patients according to risk of disease progression. In this study, we report that high expression of c-Myb protein, determined by immunohistochemistry (IHC), associates with better overall and disease-free survival (OS, DFS) in a cohort of 103 patients. Although MYB has been previously considered to act as oncogene in CRC, our further analysis of datasets deposited in PrognoScan and SurvExpress databases confirmed that high MYB expression largely associates with good prognosis in CRC. As therapies targeting c-Myb have been developed and tested in preclinical studies, we believe that further studies are needed for detailed understanding of c-Myb function in CRC, before the c-Myb-targeted therapy enters clinical trials.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Cancer

ISSN

1837-9664

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

AU - Austrálie

Počet stran výsledku

5

Strana od-do

1393-1397

Kód UT WoS článku

000459711200007

EID výsledku v databázi Scopus

2-s2.0-85067297674